EGFR and non-small cell lung carcinoma: As discussed above, NSCLC patients possibly underwent the loss of T790M and acquired tertiary mutations during osimertinib treatment, and therefore it is seemingly feasible to utilize early-generation EGFR-TKIs to re-treat this group after progression on osimertinib treatment.